(News Bulletin 247) – Transgene presents to the AACR (American Association for Cancer Research) new data showing that the individualized therapeutic vaccine TG4050 from Transgene and NEC induces strong and specific immune responses against tumours.
TG4050, the first candidate from Transgene’s myvac® platform, benefits from state-of-the-art AI technologies provided by NEC.
The new positive data was generated in patients with HPV-negative head and neck cancers and ovarian cancer treated in the two Phase I trials currently evaluating TG4050.
TG4050 has demonstrated the ability to induce strong immune responses against targeted antigens in patients, a condition expected to prolong periods of remission.
Hedi Ben Brahim, Chief Executive Officer of Transgene, comments: ‘Our individualized neoantigen vaccine TG4050 continues to provide very encouraging clinical and immune response data, combined with an excellent safety profile. These results suggest that TG4050 has the potential to prolong the remission period of cancer patients who have undergone surgery. TG4050 thus gives them new hope, when they currently have no treatment options except careful follow-up’.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
